You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Position tracking and mobility assessment system for indoor monitoring of elders

    SBC: EMBEDRF LLC            Topic: NIA

    DESCRIPTION (provided by applicant): The goal of this project is to develop and evaluate a position tracking and mobility assessment system that will enable the elderly to live longer and more safely at home or in an assisted living facility. The ability to move is a critical function tat underlies the quality of life for the elderly. Changes in mobility such as speed of walking have been shown to ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Resonant-Photonic-Device-Enhanced SERS Substrate with Pinpointed Plasmonic-Active

    SBC: Omega Optics, Inc.            Topic: NIEHS

    DESCRIPTION (provided by applicant): The use of Surface Enhanced Raman Scattering (SERS) for biomolecule detection has been restricted due to the great difficulty of fabricating ultrasensitive and reproducible surface-plasmonic-resonance (SPR) substrates.Therefore, detecting extremely small amount of biomolecules for clinical application is significantly limited. In this STTR Phase II research, w ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Alafair Biosciences develops cross-linked polysaccharide hydrogel films to addres

    SBC: ALAFAIR BIOSCIENCES, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): The goal of this STTR project is to develop a pre-formed, naturally-based hydrogel postoperative adhesion barrier with improved handling characteristics, laparoscopic deliverability, and consistent efficacy. Our technology is based on a novel, patented process that imparts exceptional elasticity and toughness on normally brittle, weak materials. Postoperative a ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. IYG-Family: Beyond the talk to effective pregnancy, STI, and HIV prevention

    SBC: Radiant Creative Group, LLC            Topic: NICHD

    DESCRIPTION (provided by applicant): The goal of this 3 year Fast-Track STTR is to develop and evaluate a home-based intervention ('it's Your Game- Family') to provide age-appropriate sexual health life skills education and training for children (11-14 years) and to enhance parents' skills and self-confidence in support of this training. IYG-Family (IYG-F) will be an on-line g ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Biochemical Diagnosis for Creutzfeldt-Jakob disease

    SBC: Amprion, Inc.            Topic: NINDS

    DESCRIPTION (provided by applicant): Human prion diseases are infectious and invariably fatal forms of neurodegenerative diseases, including sporadic Creutzfeldt-Jakob disease (sCJD), the most common form, and variant CJD (vCJD) which is associated to consumption of cattle meat infected by bovine spongiform encephalopathy. Currently there is not sensitive, objective and non-invasive biochemical di ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Automated point-of-care identification of innocent Still's murmur in children

    SBC: AUSCULTECH DX LLC            Topic: NHLBI

    PROJECT SUMMARY The overall goal of the proposed research and technology transfer effort is to develop a low-cost, point-of-care, mobile device-based technology for automated identification of Stillandapos;s murmur, the most common innocent (benign and harmless) heart murmur of childhood. This novel technology could reduce the current rate of over half a million children unnecessarily referred to ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Gallium 68 Tilmanocept for PET Imaging of Atherosclerosis Plaques

    SBC: Navidea Biopharmaceuticals, Inc.            Topic: NHLBI

    Myocardial infarctionsMIor heart attacksischemic strokesISand peripheral artery diseasePADtogether considered cardiovascular diseaseCVDare all commonly caused by the same underlying pathologyatherosclerosisMIs and ISs are the leading causes of death and disability worldwideAtherosclerosis is a progressive pathology that develops asymptomatically over the course of many years as inflammatory plaque ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.

    SBC: Vova Ida, LLC            Topic: 999

    SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. The Daily Progress System- A Recovery Support Tool to Reduce Health Disparities in Outpatient Substance Use Treatment

    SBC: COG ANALYTICS, LLC            Topic: 102

    ABSTRACTSubstance use disordersSUDsincluding opioid use disorderscontinue to be one of the most serious public health issues in the USleading to negative physical and mental health problemsfamily disruptionand premature deathAfrican Americans with drug use histories that are under criminal justice supervision are particularly vulnerable to experiencing the negative consequences associated with SUD ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Integrin Activation as a Treatment for Leukocyte Adhesion Deficiencies

    SBC: 7 Hills Pharma LLC            Topic: NIAID

    Leukocyte adhesion deficiency type ILADis a rare and often fatal primary immunodeficiencyIt is caused by autosomal recessive mutations in the gene ITGBwhich encodes CDthe commonsubunitof thefamily of integrin cell adhesion molecules that are specifically expressed on cells of hematopoietic origin like leukocytesAs a result of decreased function ofintegrinsleukocytes cannot extravasate from the vas ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government